[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353848-105":59,"doc-detail-353848-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evaluation-of-mixed-response-in-tumor-size-and-survival-in-patients-with-rare-cancers-treated-with-dual-checkpoint-inhibitor-therapy-dart-swog-s1609","Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)","","Mixed response, where different lesions within the same patient show discordant responses to treatment, remains poorly understood. To clarify how mixed response shapes patient survival, a retrospective analysis created three mixed-response definitions in patients with rare cancers receiving dual checkpoint blockade (ipilimumab plus nivolumab) using data from 52 baskets in the DART SWOG S1609 trial.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluation-of-mixed-response-in-tumor-size-and-survival-in-patients-with-rare-cancers-treated-with-dual-checkpoint-inhibitor-therapy-dart-swog-s1609/353848/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluation-of-mixed-response-in-tumor-size-and-survival-in-patients-with-rare-cancers-treated-with-dual-checkpoint-inhibitor-therapy-dart-swog-s1609/353848.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is mixed response in this study?","Question",{"text":112,"@type":113},"Mixed response refers to discordant responses among different lesions within the same patient during treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was mixed response defined in the analysis?",{"text":117,"@type":113},"Three definitions were tested, including RECIST discordance across lesions and two lesion-level size-change approaches using 5 mm and 1 mm cut-offs.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about survival outcomes?",{"text":121,"@type":113},"Mixed response was significantly associated with worse overall survival and progression-free survival, including among patients classified as stable by RECIST.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353848,1790230456,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Open access Original research  \n Evaluation of mixed response in tumor  \nsize and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)  \nYoung Kwang Chae  ,1 Megan Othus  ,2 Jiyon Lyu  ,1,3 Seyoung Lee,1 Seungwon Paik,1 Eliana Dietrich,4 Chan Mi Jung,1 Liam Il-Young Chung,1 Sandip Patel,5 Razelle Kurzrock6  \nTo cite: Chae YK, Othus M, Lyu J, et al. Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609) . Journal for ImmunoTherapy of Cancer 2026;14:e013260 . doi:10 . 1136/ jitc-2025-013260  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-013260](jitc-2025-013260)) .  \nYKC, JL, SL and SP contributed equally.  \nAccepted 04 March 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Young Kwang Chae; [chaelabmeeting@gmail.com](chaelabmeeting@gmail.com)  \nABSTRACT  \nBackground Mixed response, where different lesions within the same patient show discordant responses to treatment, remains poorly understood. To better understand the complex effects of mixed response on patient survival, we devised three different definitions of mixed response. This retrospective analysis provides the first evaluation of the association between mixed response and survival outcomes in patients with rare cancers treated with dual checkpoint blockade using ipilimumab plus nivolumab, based on data from 52 baskets in the DART SWOG S1609 trial.  \nMethods We included 438 patients with Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1-measurable disease and at least two target lesions, after exclusions for ineligibility, early death, or missing data. Overall survival (OS) and progression-free survival (PFS) were compared using log-rank tests and Cox regression, stratified by basket and using a day 65 landmark. A mixed response was evaluated using three definitions:  \nMethod 1—RECIST discordance across lesions; Method 2—presence of ≥1 lesion with >5 mm increase or ≥1 with >5 mm decrease; and Method 3—same as Method 2 but with a 1 mm cut-off.  \nResults Mixed response was significantly associated with worse OS and PFS using both Method 1 (OS: HR 1.80; PFS: HR 1 .58) and Method 2 (OS: HR 1 .55; PFS: HR 1.57) compared with “all SD/stable per lesion”. Among patients classified as “SD by RECIST”, those who exhibited a mixed per lesion response according to Method 1 had significantly worse OS (median 9.9 months (8.8–12.4)) than those with a non-mixed per lesion response (median 22.7 months (19 .2–32.0)) . Further stratification showed that any lesion increasing >5 mm was linked to worse outcomes (OS: HR >2 .37, p\u003C0 .05) .  \nConclusions Mixed response was significantly associated with worse survival outcomes in patients treated with dual immune checkpoint inhibitors, even among those with RECIST-defined stable disease. Our findings suggest that the “worst”-responding lesion drives prognosis, underscoring the limitations of RECISTin capturing clinically relevant heterogeneity. This study highlights the need to incorporate lesion-level assessment into immunotherapy decision-making and provides a foundation for guiding earlier transition to the next line  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ Mixed response, defined as discordant responses among lesions within the same patient, has been observed in up to 22% of patients receiving immune checkpoint inhibitors. Prior studies have largely focused on single tumor types and lacked standardized definitions of mixed response. The prognostic impact of lesion-level heterogeneity remains unclear.\u003Cbr>WHAT THIS STUDY ADDS |\n| ⇒ This is the first la","cbCaio3xU0yk7LYP","https://ap.wps.com/l/cbCaio3xU0yk7LYP","pdf",2691824,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## RECIST and tumor heterogeneity","[{\"question\":\"What is mixed response in this study?\",\"answer\":\"Mixed response refers to discordant responses among different lesions within the same patient during treatment.\"},{\"question\":\"How was mixed response defined in the analysis?\",\"answer\":\"Three definitions were tested, including RECIST discordance across lesions and two lesion-level size-change approaches using 5 mm and 1 mm cut-offs.\"},{\"question\":\"What did the study find about survival outcomes?\",\"answer\":\"Mixed response was significantly associated with worse overall survival and progression-free survival, including among patients classified as stable by RECIST.\"}]","Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609) | PDF",1790107535,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ee6cde85d03e0865d65dd62846ab634.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba7a4c11b7d65ed6b2775ac6b94bc87e.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40e86fea02ecc06abaa0ff8e2ddb75eb.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/796484c9e3c1775afdd61079d2daf706.webp",980,1306]